Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to understand and the willingness to sign a written informed consent document;~2. Any prior therapy is permitted except prior therapy with PD1/PDL1 inhibitor.~3. Histologic diagnosis of metastatic renal cell carcinoma or urothelial cancer;~4. Patients must have at least 2 distinct measurable metastatic sites at least 1 cm or larger in their largest diameter per RECIST 1.1~5. Patients must have adequate organ and marrow function as defined by initial laboratory tests.~6. At least 2 weeks since last chemotherapy and 4 weeks since last immunotherapy treatment.~7. Performance status Eastern cooperative oncology group (ECOG) 0-1~8. Men and women, ages \> 18 years of age.~9. Life expectancy \> 3 months~10. Stable brain metastases for at least 4 weeks and not steroid dependent~11. Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 8 weeks after the study in such a manner that the risk of pregnancy is minimized. Should a woman become pregnant or suspect she is pregnant while she is enrolled in this study, she should inform her treating physician immediately.~Exclusion Criteria:~1. Patients having no lesions outside the field of radiation thus nullifying the ability to measure an abscopal effect;~2. Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix;~3. Autoimmune/auto inflammatory disease: Patients with a history of inflammatory bowel disease are excluded from this study as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \[scleroderma\], Systemic Lupus Erythematosus, autoimmune vasculitis \[e.g., Wegener's Granulomatosis\];~4. Any underlying medical or psychiatric condition, which in the opinion of the Investigator, will make the administration of study drug hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea;~5. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to one month prior to or after any dose of PD-1/PDL-1 blocking antibody).~6. A history of prior treatment with PD-1/PDL-1blocking antibody;~7. Patients who have had immunotherapy within 4 weeks prior to entering the study.~8. Concomitant therapy with any of the following: interleukin -2 (IL-2), interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigation therapies; or chronic use of systemic corticosteroids;~9. Patients undergoing therapy with other investigational agents or other chemotherapy agents;~10. Women who:~    1. are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after cessation of study drug, or~   2. have a positive pregnancy test at baseline, or~   3. are pregnant or breastfeeding~11. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious) illness

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm A - immunotherapy alone (Type: ACTIVE_COMPARATOR): Patients with Renal Cell carcinoma will receive Nivolumab alone Days 1, 15, 29, 43 and 57.~Patients with Urothelial cancer will receive Atezolizumab or Pembrolizumab on Days 1, 22, 43 and 64.
- Arm B - Radiation & immunotherapy (Type: ACTIVE_COMPARATOR): Radiation is given to one lesion, 30 Gy in 3 fractions of 10 Gy, every other day. On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days.

Based on this trial design, predict the completion outcome and termination type (if applicable).